Human kallikrein 10 ELISA development and validation in breast cancer sera

Clinical Biochemistry

Volumn 40, Issue 13-14, 2007, Pages 1057-1062

  Ewan King, Lindsay ^a   Li, Xiaogang ^a   Cheikh Saad Bouh, Kane ^a   Pedneault, Marc ^a   Chu, Chee Wui ^a  

^a IBEX Pharmaceuticals   (Canada)

Author keywords

Breast Cancer; ELISA; hK10; Serum

Indexed keywords

ENZYME; KALLIKREIN; KALLIKREIN 10; KALLIKREIN 10 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; RECOMBINANT KALLIKREIN 10; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BREAST CANCER; BREAST DISEASE; CANCER PATIENT; CANCER STAGING; COLORIMETRY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYSTIC FIBROSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS;

EID: 34548133514     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2007.05.008     Document Type: Article

References (13)

1. Liu X.L., Wazer D.E., and Watanabe K. Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res. 56 (1996) 3371-3379
2. Diamandis E., Yousef G., Clements J., Ashworth L., Yoshida S., Eglrud T., et al. New nomenclature for the human tissue kallikrein gene family. Clin. Chem. 46 (2000) 1855-1858
3. Goyal J., Smith J.M., Wazer D.E., Lee S.W., and Band V. The role for NES1 serine protease as a novel tumour suppressor. Cancer Res. 58 (1998) 4782-4786
4. Dhar S., Bhargava R., Yunes M., Li B., Goyal J., Naber S.P., et al. Analysis of normal epithelial cell specific-1 (NES1)/kallikrein 10 mRNA expression by in situ hybridization, a novel marker for breast cancer. Clin. Cancer Res. 7 11 (2001) 3393-3398
5. Yunes M.J., Neuschatz A.C., Bornstein L.E., Naber S.P., Band V., and Wazer D.E. Loss of expression of the putative tumour suppressor NES1 gene in biopsy-proven ductal carcinoma in situ predicts for invasive carcinoma at definitive surgery. Int. J. Radiat. Oncol. Biol. Phys. 56 3 (2003) 653-657
6. Luo L.Y., Diamandis E.P., Look M.P., Soosaipillai A.P., and Foekens J.A. Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance. Br. J Cancer 86 11 (2002) 1790-1796
7. Luo L.Y., Katsaros D., Scorilas A., Fracchioli S., Bellino R., van Gramberen M., et al. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Can. Res 63 (2003) 807-811
8. Luo L.Y., Grass L., Howarth D.J., Thibault P., Ong H., and Diamandis E.P. Immunofluorometric assay of human kallikrein 10 and its identification in biological fluids and tissues. Clin. Chem. 47 2 (2001) 237-246
9. Luo L.Y., Katsaros D., Scorilas A., Fracchioli S., Piccinno R., dela Longrais I.A.R., et al. Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clin. Cancer Res. 7 (2001) 2372-2379
10. Li B., Goyal J., Dhar S., Dimri G., Evron E., and Sukumar S. CpG methylation as a basis for breast tumour-specific loss of NES1/kallikrein 10 expression. Cancer Res. 61 (2001) 8014-8021
11. Sidioropoulos M., Pampalakis G., Sotiropoulou G., Katsaros D., and Diamandis E.P. Down regulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers. Tumour Biol. 26 6 (2005) 324-336
12. Zhang Y., Bhat I., Zeng M., Jayal G., Wazer D.E., Band H., et al. Human kallikrein 10, a predictive marker for breast cancer. Biol. Chem. 387 6 (2006) 715-721
13. Petraki C.D., Karavana V.N., and Diamandis E.P. Human kallikrein 10 expression in normal tissues: an immunohistochemical study. J. Histochem. Cytochem. 50 9 (2002) 1247-1261